Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation  by Lewalter, Thorsten
C
D
f
R
A
I
i
w
p
f
o
p
a
d
p
J
r
w
e
1
2
3
Journal of the American College of Cardiology Vol. 55, No. 10, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00
Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
4
5
f
o
t
h
c
m
c
p
s
I
T
F
i
s
c
*
*
H
D
S
R
B
G
E
Romparative Efficacy of
ronedarone and Amiodarone
or the Maintenance of Sinus
hythm in Patients With
trial Fibrillation
n ATHENA (A Trial With Dronedarone to Prevent Hospital-
zation or Death in Patients With Atrial Fibrillation), dronedarone
as shown to reduce morbidity and cardiovascular mortality in
atients with atrial fibrillation (AF) who had additional risk factors
or death (1). Available antiarrhythmic drugs are limited by a lack
f effect on reducing morbidity and their potential for serious
roarrhythmia or extracardiac toxic effects. However, no morbidity
nd mortality end point trial is available for a direct comparison.
Every effort to quantify the relative efficacy and safety of
ronedarone is welcome to define its role in improving the
rognosis of patients with AF. In the September 15 issue of the
ournal (2), a meta-analysis was published showing that droneda-
one is less effective than amiodarone in maintaining sinus rhythm
hile showing a trend toward reduced mortality and fewer adverse
vents.
A careful exploration, however, reveals a number of inconsistencies:
. Particularly evident is the reported lack of efficacy of droneda-
rone for the prevention of recurrent AF (odds ratio: 0.79; 95%
confidence interval: 0.33 to 1.87). This result is largely based on
EURIDIS (EURopean trial In atrial fibrillation or flutter patients
receiving Dronedarone for the maIntenance of Sinus rhythm)/
ADONIS (American-Australasian trial with DronedarONe In
atrial fibrillation or flutter patients for the maintenance of Sinus
rhythm) trials (3) for which Piccini et al. (2) reported a trend for
an increased recurrence with dronedarone (Fig. 2A of their
paper [2]; odds ratio: 1). However, this is not consistent with
the original publication (hazard ratio: 0.75; 95% confidence inter-
val: 0.65 to 0.87). Piccini et al. (2), in recalculating the results,
obviously falsely used the number of patients at 12 months,
excluding those with a drug exposure of5 days. This error has a
direct impact on the overall reported relative efficacy of droneda-
rone and amiodarone, resulting in a more favorable odds ratio for
amiodarone and a lower number of AF recurrences.
. In DAFNE (Dronedarone Atrial FibrillatioN study after Electri-
cal Cardioversion) (4), 90% of 48 patients receiving placebo and
65% of 54 patients receiving dronedarone (800 mg) had recurrence
of AF at 6 months. Piccini et al. (2) extrapolated these numbers to
the group size of the safety population (placebo n  66, drone-
darone 800 mg n  76), which is not feasible.
. In ATHENA, 290 of 2,291 patients taking dronedarone and
187 of 2,313 patients taking placebo discontinued treatment
because of adverse events. Piccini et al. (2) related these
discontinuations to the 2,301 and 2,327 patients of theintention-to-treat population. However, 10 patients random-
ized to dronedarone and 14 randomized to amiodarone never
received the study drug.
. Piccini et al. (2) restricted data of GEFACA (Grupo de
Estudio de Fibrilacio´n Auricular Con Amiodarona) (5) to
patients with successful cardioversion only, whereas all patients
including those with unsuccessful cardioversion were consid-
ered for DAFNE.
. In SAFE-T (Sotalol Amiodarone Atrial Fibrillation Efficacy
Trial) (6), patients were not considered in whom AF recurred
within the first 28 days. Therefore, the data used for the
meta-analysis are likely to overestimate the effect of amiodarone
on reducing the recurrence of AF.
Further to these obvious discrepancies, the Methods section
ails to report whether important variables like the mean duration
f follow-up; differences in the proportion of paroxysmal, persis-
ent, and permanent atrial fibrillation; and anticoagulation use
ave been accounted for in the analyses.
Taken together, false aggregation of available randomized
linical trials has led to an underestimation of the true antiarrhyth-
ic effect of dronedarone and should be corrected. However, it
annot be overemphasized that sinus rhythm maintenance in
atients with AF might not translate into better outcomes and
urvival as demonstrated in trials like the PIAF (Pharmacological
ntervention in Atrial Fibrillation) trial (7), CTAF (Canadian
rial of Atrial Fibrillation) (8), and AFFIRM (Atrial Fibrillation
ollow-up Investigation of Rhythm Management) (9). Therefore, it
s time for a reappraisal of end points in the treatment of AF that
hould focus on true patient-related benefits like hospital stays and
ardiovascular and cerebrovascular events (10).
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ronedarone Is Superior to Placebo
he Case for Optimism
read with interest the study by Piccini et al. (1) that evaluated
ronedarone for treating atrial fibrillation (AF). I agree with the
rimary conclusion that amiodarone is more effective than drone-
arone for maintenance of sinus rhythm, as would be expected on
he basis of the DIONYSOS (Efficacy and Safety of Dronedarone
ersus Amiodarone for the Maintenance of Sinus Rhythm in
atients with Atrial Fibrillation) trial (2). However, I have concern
bout the dronedarone data that might have mistakenly led to an
verly negative appraisal of its effect.
In Figure 2A of the paper (1), the authors present an odds ratio
lot for EURIDIS (EURopean trial In atrial fibrillation or flutter
atients receiving Dronedarone for the maIntenance of Sinus
hythm) and ADONIS (American-Australasian trial with Drone-
arONe In atrial fibrillation or flutter patients for the maintenance
f Sinus rhythm) (3). The data as presented suggest that placebo
ad efficacy comparable to dronedarone in these studies, which
irectly contradicts the studies’ conclusions. The answer to this
nconsistency lies in the supporting data to the right of the odds
atio plot. For EURIDIS, the denominators of 411 and 201
atients/treatment arm come from the second line of Table 2 of
he trial’s publication (3). The numerators are supposed to repre-
ent the number of patients with recurrent AF and are also taken
rom Table 2, 5th line of data (1).
These numbers do not make sense as representing the number
f patients with recurrent AF at 1 year. They would correspond to
4.7% (307 of 411) and 73.6% (148 of 201) with recurrent AF at
year for dronedarone and placebo, respectively, and thus would
how no difference between the 2 treatments. The actual reported
ecurrence rates of AF at 1 year (Table 2, line 3 [1]) are 67.1% and
7.5% for dronedarone and placebo, respectively. Instead, I believe
hat the number of patients presented in line 5 of the table likely
epresents the denominator for the analysis that follows, much like
he number of patients in line 2 also is a denominator, and absolute
umbers of patients with recurrent AF are not specified, favoring
resenting these data as percentages (1). It is also possible that the eumbers in line 5 present some other subselection of the total
atient population, but it is inconsistent with the results of
URIDIS to assume that they represent the number of patients
ith recurrent AF. The same number sources are used for
DONIS. This artificially makes dronedarone seem the same as
lacebo in terms of AF recurrence rate at 1 year, a finding that
ignificantly differs from the data in Table 2 and the Kaplan-Meier
lots in Figure 2 (3).
While awaiting clarification from the authors of EURIDIS and
DONIS, there seems to be an error here that creates an overly
egative conclusion as to the effect of dronedarone. After all,
ronedarone has already been demonstrated in several studies to be
uperior to placebo (3,4) and not equal to it, as is suggested by the
rticle by Piccini et al. (1).
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eply
e appreciate the opinions of Dr. Lewalter regarding our meth-
dology (1), particularly the use of intention-to-treat populations.
he meta-analysis was constructed with conservative assumptions
o reduce the risk of type I error. From this perspective, when
stimating potential differences among treatments, biases that
ake the treatments seem more similar (including crossovers or
ailure to receive treatment) are conservative assumptions.
ntention-to-treat provides the best pragmatic estimate of a given
herapeutic strategy (in this case, therapy with dronedarone vs.
miodarone) (2). Often disagreement arises over the exact defini-
ion of intention-to-treat in an individual trial. In our meta-
nalysis we attempted to include patients in the denominator
ccording to treatment allocation at the time of randomization.
Although the primary end point in EURIDIS (EURopean trial In
trial fibrillation or flutter patients receiving Dronedarone for the
aIntenance of Sinus rhythm) and ADONIS (American-
ustralasian trial with DronedarONe In atrial fibrillation or flutter
atients for the maintenance of Sinus rhythm) (3) was the time to
ecurrence of atrial fibrillation (AF), in our analysis the primary
fficacy end point was recurrent AF at follow-up. This approach was
